Thanks to all who attended the CU Anschutz Innovation Forum
CU Innovations, Startup Toolbox and Academia Industry Alliance (AIA) hosted a 3-day event on June 10-12th that highlighted the diversity of innovation at the University of Colorado Anschutz Medical Campus.
Engaging presentations and panel discussions demystified the innovation journey. Key sessions covered company formation, building inclusive teams and career opportunities. CU researchers, start-ups and industry partners participated and networked at this successful event!
Congratulations to the winners of the Venture Showcase: NowVitals, pitched by Robin Deterding, MD, and Vināśa Oncology, pitched by Sujatha Venkataraman, PhD!
(1/19)
(2/19)
(3/19)
(4/19)
(5/19)
(6/19)
(7/19)
(8/19)
(9/19)
(10/19)
(11/19)
(12/19)
(13/19)
(14/19)
(15/19)
(16/19)
(17/19)
(18/19)
(19/19)
Agenda
Building upon the success of last year's Stories of Women-Led Innovation Event, this forum continued highlighting the achievements and challenges faced by our women innovators and demystifying the innovation pathway through presentations and panel discussions. Sessions covered intellectual property protection, building inclusive teams and addressing bias in the context of academic innovation.
Attendees were excited to hear from our keynote speaker, Gitanjali Rao, aspiring scientist, inventor and author!
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
This event aimed to educate and inspire entrepreneurs at all stages. Featuring panels on company formation, funding biomedical discoveries and creating strategic alliances, each session included interactive elements and the chance to network with potential partners from the Anschutz campus and beyond.
Attendees got to know Jodie Morrison, CEO of Q32 Bio, and Kimberly Muller, Executive Director of CU Innovations, through their Fireside Chat Keynote.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Congratulations to the judge vote winner, NowVitals pitched by Robin Deterding, MD, and the audience vote winner, Vināśa Oncology pitched by Sujatha Venkataraman, PhD!
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
With sessions featuring scientific talks, career panels, and a 2-hour networking lunch, RMBTS offered a prime platform to highlight scientific advancements and career opportunities, and foster collaboration within Colorado's scientific community.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Mike Schurr PhD
Microbiologist Associate, Azodent
About Mike Schurr, PhD:
Dr. Schurr is an Associate Professor in the department of Immunology and Microbiology and has over 30 years of experience in bacterial pathogenesis research. He is the founder and president of Azodent, a start-up company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecules as viable clinical candidates to disrupt biofilms. Azodent’s lead compound, Acrylated Hydroxy-Azobenzene (AHA), has shown strong efficacy, both in vitro and in vivo, in killing Streptococcus spp. and disrupting biofilms formed by several Gram-negative pathogens. Azodent has been awarded an Anschutz Accelerator Innovation award to 3D print dentures and dental filling materials containing AHA. Azodent is also the recipient of a RadLaunch award from the RadTech Association.
About Azodent:
Azodent is an early clinical stage bio-materials company developing targeted materials to treat dental caries and to incorporate these materials into dental appliances.
Azodent is focused on the development and commercialization of our lead compound, AHA. The company’s immediate objective is the completion of biocompatibility and efficacy studies in preparation for a 510K submission. Our long-term vision is to grow Azodent into a cutting-edge materials discovery and development company that can turn novel biological insights into actionable clinical treatments.
Azodent has designed a polymer coating that can be used to prevent biofilm accumulation and infections on implants, prostheses, catheters, and endoscopes. This technology has a wide range of potential applications in the industrial coatings market, including for non-stick coatings, touch screens, and de-icing coatings for aircraft.
Additionally, the photo-responsive material can also selectively inhibit dental cavities-causing bacteria, and disrupt biofilms formed on it. Such genus-specific inhibition and biofilm disruptive properties within the same material are rare in dentistry, therefore the dental market is likely the initial market for this technology.
Event Sponsors
Thank you to our sponsors for making this forum possible! We are greatly appreciative of your continued support.
PLATINUM SPONSORS:
SPONSORS:
